Didesmethylrocaglamide 是一种 Rocaglamide 的衍生物,也是一种有效的真核起始因子 4A (eIF4A) 抑制剂。Didesmethylrocaglamide 具有有效的生长抑制活性,IC50为 5 nM。Didesmethylrocaglamide 抑制多种促进生长的信号通路,并诱导肿瘤细胞凋亡 (apoptosis)。抗肿瘤活性。
生物活性 | Didesmethylrocaglamide, a derivative of Rocaglamide, is a potenteukaryotic initiation factor4A (eIF4A)inhibitor. Didesmethylrocaglamide has potent growth-inhibitory activity with anIC50of 5 nM. Didesmethylrocaglamide suppresses multiple growth-promoting signaling pathways and inducesapoptosisin tumor cells. Antitumor activity[1][2]. |
IC50& Target | Eukaryotic initiation factor 4A (eIF4A)[1] |
体外研究 (In Vitro) | Didesmethylrocaglamide (5 nM, and 10 nM; 72 hours; MPNST cells) treatment arrests MPNST cells at G2-M, increases the sub-G1 population, induces cleavage of caspases and PARP, and elevates the levels of the DNA-damage response marker γH2A.X, while decreasing the expression of AKT and ERK1/2[1]. Didesmethylrocaglamide inhibits MPNST cell proliferation by inducing cell cycle arrest at G2/M and subsequently, cell death. Didesmethylrocaglamide-treated 697-R cells exhibits IC50values is very similar to those of parental 697 cells (4 vs 3nM of IC50, respectively)[1]. Didesmethylrocaglamide induces apoptosis in both neurofibromatosis type 1 (NF1)-expressing and NF1-deficient MPNST cells, possibly subsequent to the activation of the DNA damage response. Didesmethylrocaglamide-treated sarcoma cells show decreased levels of multiple oncogenic kinases, including insulin-like growth factor-1 receptor[1].
Western Blot Analysis[1] Cell Line: | Malignant peripheral nerve sheath tumors (MPNST) cells | Concentration: | 5 nM, and 10 nM | Incubation Time: | 72 hours | Result: | Induced cleavage of caspases and PARP, and elevated the levels of the DNA-damage response marker γH2A.X. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(209.42 mM;Need ultrasonic) 配制储备液 1 mM | 2.0942 mL | 10.4710 mL | 20.9420 mL | 5 mM | 0.4188 mL | 2.0942 mL | 4.1884 mL | 10 mM | 0.2094 mL | 1.0471 mL | 2.0942 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.24 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.24 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.24 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|